Danish pharma company seeks $13 million asset sale amid US class action
A Copenhagen-based biopharmaceutical company is set to sell its assets to US pharma group KemPharm as part of a restructuring announced last week, after failing to secure European approval to market a new drug.
To read more
Subscribe to Global Restructuring Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Restructuring Review experts.